To circumvent the in vivo instability of
5-iodo-2'-deoxyuridine (
IUdR), a 2'-fluorine-substituted analogue, 5-iodo-1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)uracil (
FIAU) recently has been introduced. To facilitate the preparation of radioiodinated
FIAU as well as its astatinated analogue, a
tin precursor, 5-trimethylstannyl-1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)ura
cil (FTAU) was synthesized. Both [125/131I]
FIAU and 5-[211At]astato-1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)
uracil (FAAU) were prepared from FTAU in more than 85% radiochemical yield under mild conditions. The in vitro serum stability of both
fluorine-substituted derivatives was higher than that of the corresponding unsubstituted parents. The enhanced stability of fluorinated derivatives was even more apparent in whole blood. The uptake of [125I]
FIAU in D-247 MG human
glioma cells in vitro was 20-fold higher than that of [125I]
IUdR over an activity concentration range of 5-100 kBq/mL; the uptake of FAAU was not significantly different from that of 5-[211At]astato-2'-
deoxyuridine (AUdR). Accumulation of radioiodine in mouse thyroid in vivo with [131I]
FIAU was fivefold lower than [125I]
IUdR, indicating that the former was less susceptible to deiodination. The tissue uptake of FAAU was similar to that reported for AUdR.